PepGen Class Action Lawsuit
Analysis based on 18 articles · First reported Jun 11, 2025 · Last updated Aug 05, 2025
The class action lawsuit against PepGen is likely to negatively impact its stock price and investor confidence due to allegations of securities fraud. This event highlights the regulatory risks in the biotechnology industry, particularly concerning product development and approval processes by the United States — Food and Drug Administration.
Levi & Korsinsky has initiated a class action securities lawsuit against PepGen, alleging that the company made false and misleading statements to investors between March 7, 2024, and March 3, 2025. The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was less effective and safe than represented, and that its phase two CONNECT2 study was deficient for United States — Food and Drug Administration approval. Consequently, PepGen was likely to halt the CONNECT2 study, and its clinical, regulatory, and commercial prospects were overstated. Investors who suffered losses during this period have until August 8, 2025, to request to be appointed as lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard